Better Survival in Refractory CRC With Chemo Plus Bevacizumab, Real-World Study Says

By News Health
1 month Ago

(MedPage Today) — Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF inhibitor bevacizumab (Avastin) to chemotherapy, data from a real-world analysis showed.
A propensity…

Source link : https://www.medpagetoday.com/hematologyoncology/coloncancer/120069

Author :

Publish date : 2026-02-26 21:45:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Venetoclax Combo Shows Promise in Younger Patients With AML

New Evidence Strengthens the Case for Iatrogenic Alzheimer’s

Why Encouragement May Not Improve Motivation in Depression

Here's Who Topped This Year's 'Best Medical Schools' Rankings

Disruption expected as six-day doctors' strike begins

Alzheimer's Risk May Be Influenced by Flu Shots